AusperBio Therapeutics, Inc., a pioneering biotechnology firm focused on targeted oligonucleotide therapies for chronic hepatitis B (CHB), has announced the successful completion of a $37 million Series A financing round. This funding, spearheaded by existing investor InnoPinnacle Fund and bolstered by new investors including Yuanbio Venture Capital, Qiming Venture Partners, Hankang Capital, and Genesis Capital, marks a significant leap forward for the company.
The newly acquired capital will be instrumental in advancing the clinical development of AHB-137, AusperBio’s leading product candidate. Additionally, the funds will support further development of the company’s proprietary Med-Oligo™ technology platform and its broader therapeutic pipeline.
Dr. Guofeng Cheng, co-founder and CEO of AusperBio, expressed his enthusiasm for this pivotal funding milestone: “We are deeply appreciative of the continued support from our existing investors and are excited to welcome new partners to our journey. This financing round is a testament to our scientific progress and clinical accomplishments. The combined commitment of our investors to advancing therapeutics for CHB is profoundly motivating. With this funding, along with the recent Breakthrough Therapy Designation (BTD) from China’s CDE, we are well-positioned to accelerate the clinical development of AHB-137 and move closer to offering a groundbreaking treatment for CHB patients.”
AHB-137: A Potential Game-Changer for Hepatitis B
AHB-137, an innovative unconjugated antisense oligonucleotide (ASO) developed using AusperBio’s Med-Oligo™ technology platform, aims to provide a functional cure for chronic hepatitis B. The novel ASO has demonstrated compelling results in preclinical studies and Phase 1 clinical trials, as highlighted at the 2023 and 2024 EASL™ conferences. Currently, AHB-137 is undergoing a Phase 1b trial across multiple international sites and a concurrent Phase 2 trial in China, advancing rapidly toward its goal of curing HBV.
Editorial Perspective
AusperBio’s impressive $37 million Series A funding round underscores a major advancement in the battle against chronic hepatitis B. The company’s innovative approach through the Med-Oligo™ technology platform is setting a new standard in the development of oligonucleotide therapies. With promising preclinical and early clinical data, AHB-137 stands at the forefront of potential breakthroughs in treating HBV.
The strategic direction and scientific rigor demonstrated by AusperBio suggest a significant impact on the global landscape of hepatitis B treatments. By securing robust financial backing and achieving a Breakthrough Therapy Designation, the company is well-positioned to push forward with its clinical trials and bring much-needed solutions to patients worldwide. AusperBio’s advancements could redefine the future of hepatitis B therapy and highlight the growing role of innovative biotech solutions in addressing complex medical challenges.
If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com.
